ReviewFrontiers in cardiovascular medicine2023
Anabolic androgenic steroids and cardiomyopathy: an update.
Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Treatment with a selective androgen receptor modulator (RAD140) is linked to better cardiac function, with male-specific effects that are graded by interleukin-6.GeroScience · 2026Article
- Review
- Microscopic cardiac pathology in forensic autopsies: a comparative study of anabolic androgenic steroid users and non-users.International journal of legal medicine · 2026Article
- Sex Hormone Supplementation and Cardiovascular Disease Risk.Medicina (Kaunas, Lithuania) · 2026Review
- Article
- Treatment of Symptomatic Male Hypogonadism with New Oral Testosterone Therapies: A Comparative Review of Jatenzo, Tlando, and Kyzatrex.Medicines (Basel, Switzerland) · 2025Review
- Gender Differences in Anti-Doping Rule Violations Based on a 19-Year Data Analysis from the Serbian Anti-Doping Agency: National Study.Sports (Basel, Switzerland) · 2025Article
- Impact of Anabolic-Androgenic Steroid Abuse on the Cardiovascular System: Molecular Mechanisms and Clinical Implications.International journal of molecular sciences · 2025Review
- Anabolic-Androgenic Steroids Induced Cardiomyopathy: A Narrative Review of the Literature.Biomedicines · 2025Review
- Harm reduction measures in a recreational gym user with anabolic androgenic steroid dependence: a case report in the context of current best clinical practice.Harm reduction journal · 2025Article
- Best Practice Guidance for Male Individuals Using Anabolic Androgenic Steroids in Recreational Sports Within Primary Care: Protocol for a Modified Delphi Consensus Study.JMIR research protocols · 2025Article
- Cardiac structure and function in anabolic-androgenic steroid users: a 16-year follow-up study.Open heart · 2025Article
- Ameliorating and therapeutic impact of nano ferrite-chitosan-curcumin nanoparticles against nandrolone decanote induced renal toxicity, inflammation, and oxidative stress in male rats.Toxicology research · 2025Article
- Evaluation of implementing drug checking services for anabolic androgenic steroids in Switzerland: a pilot study.Harm reduction journal · 2025Article
- Steroid-Induced Cardiomyopathy: Insights From a Systematic Literature Review and a Case Report.Clinical case reports · 2025Article
- Economic and equity evaluation of age restrictions on over-the-counter diet pills and muscle-building supplements.Health affairs scholar · 2025Article
- Coronary Microvascular Dysfunction Years After Cessation of Anabolic Androgenic Steroid Use.JAMA network open · 2024Article
- Article
- Association of Anabolic Steroid Use With Hypertension and Cardiomyopathy: A Case Study.Cureus · 2024Article
- The Use of Anabolic Steroids by Bodybuilders in the State of Sergipe, Brazil.European journal of investigation in health, psychology and education · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anabolic androgenic steroids (AAS) include endogenously produced androgens like testosterone and their synthetic derivatives. Their influence on multiple metabolic pathways across organ systems results in an extensive side effect profile. From creating an atherogenic and prothrombotic milieu to direct myocardial injury, the effects of AAS on the heart may culminate with patients requiring thorough cardiac evaluation and multi-disciplinary medical management related to cardiomyopathy and heart failure (HF). Supraphysiological doses of AAS have been shown to induce cardiomyopathy via biventricular dysfunction. Advancement in imaging including cardiac magnetic resonance imaging (MRI) and additional diagnostic testing have facilitated the identification of AAS-induced left ventricular dysfunction, but data regarding the impact on right ventricular function remains limited. Emerging studies showed conflicting data regarding the reversibility of AAS-induced cardiomyopathy. There is an unmet need for a systematic long-term outcomes study to empirically evaluate the clinical course of cardiomyopathy and to assess potential targeted therapy as appropriate. In this review, we provide an overview of the epidemiology, pathophysiology and management considerations related to AAS and cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.